(PharmaNewsWire.Com, September 28, 2017 ) Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 9 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Gastrointestinal, Oncology, Central Nervous System, Dermatology, Musculoskeletal Disorders, Ophthalmology and Undisclosed which include indications Ulcerative Colitis, Psoriasis, Autoimmune Disorders, Inflammation, Inflammatory Bowel Disease, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Multiple Sclerosis, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Alopecia, Anaplastic Large Cell Lymphoma (ALCL), Arthritis, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Hypersensitivity, Lupus Erythematosus, Lupus Nephritis, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Systemic Lupus Erythematosus, T-Cell Leukemia, Unspecified, Uveitis and Waldenstrom Macroglobulinemia.
The latest report Non Receptor Tyrosine Protein Kinase TYK2-Pipeline Review, H2 2017, outlays comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
List of Tables Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Indications, H2 2017 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Number of Products under Investigation by Universities/Institutes, H2 2017 Products under Investigation by Universities/Institutes, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Pipeline by Array BioPharma Inc, H2 2017 Pipeline by Bristol-Myers Squibb Company, H2 2017 Pipeline by Nimbus Therapeutics LLC, H2 2017 Pipeline by Pfizer Inc, H2 2017 Pipeline by Portola Pharmaceuticals Inc, H2 2017 Pipeline by Sareum Holdings Plc, H2 2017 Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017 Pipeline by Theravance Biopharma Inc, H2 2017 Dormant Projects, H2 2017 Discontinued Products, H2 2017
List of Figures Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Top 10 Indications, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017 Number of Products by Molecule Types, H2 2017 Number of Products by Stage and Molecule Types, H2 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: